Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

RNA exon editing technology

- PMLiVE

Roche announces positive late-stage results for Gazyva/Gazyvaro in lupus nephritis

The disease affects approximately 1.7 million people worldwide and primarily impacts women

- PMLiVE

Roche shares positive overall survival results for Itovebi in advanced breast cancer

Approximately 56,800 new cases of breast cancer are diagnosed in the UK every year

- PMLiVE

Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy

The muscle-wasting disorder is estimated to affect one in every 5,000 male births worldwide

- PMLiVE

Roche gains rights to Innovent Biologics’ ADC candidate in deal worth over $1bn

IBI3009 targets an antigen significantly overexpressed in cancers including small cell lung cancer

- PMLiVE

Roche announces five-year results for Polivy combination in diffuse large B-cell lymphoma

Approximately 160,000 cases of the aggressive blood cancer are diagnosed globally every year

- PMLiVE

Roche expands cell therapy capabilities with $1.5bn Poseida acquisition

The deal includes a BCMA-targeting allogeneic CAR-T therapy candidate for multiple myeloma

- PMLiVE

Roche and Flare Therapeutics enter oncology partnership worth over $1.8bn

The companies will aim to discover small molecule treatments aimed at previously undrugged transcription factor targets

- PMLiVE

Roche’s Alecensa receives NICE recommendation to treat ALK-positive lung cancer

Just under 100 non-small cell lung cancer patients in England will be eligible for the drug

- PMLiVE

Jazz shares positive results for Zepzelca combination in phase 3 lung cancer study

Approximately 30,000 new cases of small cell lung cancer are reported in the US every year

- PMLiVE

Roche presents two-year data for spinal muscular atrophy treatment Evrysdi in children

The severe and progressive neuromuscular disease affects about one in every 10,000 babies

- PMLiVE

Roche’s Itovebi combination granted FDA approval for advanced breast cancer

Approximately 310,720 women will be diagnosed with invasive breast cancer in the US this year

- PMLiVE

Roche’s Genentech acquires Regor Pharmaceuticals’ CDK inhibitors for $850m upfront

One of the candidates included in the deal has already shown promise in a phase 1a advanced breast cancer study

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links